TD Cowen analyst Ken Cacciatore raised the firm’s price target on Biohaven (BHVN) to $30 from $15 and keeps a Buy rating on the shares. The firm updated its model as the Kv7 MoA in focal epilepsy is now strongly validated by robust azetukalner data. This is encouraging ahead of topline opakalim data expected mid-year, and they are optimistic the company may be able to promote on its differentiated CNS AE profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven price target raised to $27 from $24 at Goldman Sachs
- Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
- Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target
- Controversial Prasad leaving FDA, NYT reports
- Biohaven price target lowered to $10 from $11 at H.C. Wainwright